Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study
- PMID: 15809368
- DOI: 10.1161/01.CIR.0000160866.90148.76
Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study
Abstract
Background: Lipid lowering with statins prevents adverse cardiac events. Both lipid-lowering and antioxidant therapies may favorably affect vasomotor function and thereby improve ischemia.
Methods and results: In a randomized, double-blind, placebo-controlled trial, 300 patients with stable coronary disease, a positive exercise treadmill test, 48-hour ambulatory ECG with > or =1 episode of ischemia, and fasting total cholesterol of 180 to 250 mg/dL were assigned to 1-year treatment with intensive atorvastatin to reduce LDL to <80 mg/dL (n=96), intensive atorvastatin to reduce LDL to <80 mg/dL plus antioxidant vitamins C (1000 mg/d) and E (800 mg/d) (n=101), or diet and low-dose lovastatin, if needed, to reduce LDL to <130 mg/dL (n=103; control group). Ischemia end points, including ambulatory ECG monitoring and exercise treadmill testing, and endothelial assessment using brachial artery flow-mediated dilation were obtained at baseline and at 6 and 12 months. Baseline characteristics were similar in all groups. LDL decreased from approximately 153 mg/dL at baseline in the 2 atorvastatin groups to approximately 83 mg/dL at 12 months (each P<0.0001) and from 147 to 120 mg/dL in the control group (P<0.0001). During ambulatory ECG monitoring, mean number of ischemic episodes per 48 hours decreased 31% to 61% in each group (each P<0.001; P=0.15 across groups), without a change in daily heart rate activity. Mean duration of ischemia for 48 hours decreased 26% to 62% in each group (each P<0.001; P=0.06 across groups). Mean exercise duration to 1-mm ST-segment depression significantly increased in each group, but total exercise duration and mean sum of maximum ST depression were unchanged. Angina frequency decreased in each group. There was no incremental effect of supplemental vitamins C and E on any ischemia outcome. Flow-mediated dilation studies indicated no meaningful changes.
Conclusions: Intensive lipid lowering with atorvastatin to an LDL level of 80 mg/dL, with or without antioxidant vitamins, does not provide any further benefits in ambulatory ischemia, exercise time to onset of ischemia, and angina frequency than moderate lipid lowering with diet and low-dose lovastatin to an LDL level of <120 mg/dL.
Comment in
-
Intensive lipid-lowering is no more effective than diet and low-dose lovastatin for reducing ischaemia in people with heart disease. Commentary.Evid Based Cardiovasc Med. 2005 Sep;9(3):241-4. doi: 10.1016/j.ebcm.2005.06.028. Epub 2005 Jul 26. Evid Based Cardiovasc Med. 2005. PMID: 16380043 No abstract available.
Similar articles
-
Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).Am Heart J. 2004 Dec;148(6):1053-9. doi: 10.1016/j.ahj.2004.06.026. Am Heart J. 2004. PMID: 15632893
-
Vascular basis for the treatment of myocardial ischemia study: trial design and baseline characteristics.Am Heart J. 2004 May;147(5):875-82. doi: 10.1016/j.ahj.2003.10.046. Am Heart J. 2004. PMID: 15131545 Clinical Trial.
-
Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.Am J Cardiol. 2005 Sep 5;96(5A):61F-68F. doi: 10.1016/j.amjcard.2005.07.013. Am J Cardiol. 2005. PMID: 16126025 Review.
-
Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.Am Heart J. 2005 Mar;149(3):451-7. doi: 10.1016/j.ahj.2004.07.041. Am Heart J. 2005. PMID: 15864233 Clinical Trial.
-
Protecting the heart: a practical review of the statin studies.MedGenMed. 2002 Dec 10;4(4):1. MedGenMed. 2002. PMID: 12817199 Review.
Cited by
-
All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.Data Brief. 2016 Apr 27;7:1541-50. doi: 10.1016/j.dib.2016.04.059. eCollection 2016 Jun. Data Brief. 2016. PMID: 27222850 Free PMC article.
-
Pravastatin improves function in hibernating myocardium by mobilizing CD133+ and cKit+ bone marrow progenitor cells and promoting myocytes to reenter the growth phase of the cardiac cell cycle.Circ Res. 2009 Jan 30;104(2):255-64, 10p following 264. doi: 10.1161/CIRCRESAHA.108.188730. Epub 2008 Dec 18. Circ Res. 2009. PMID: 19096024 Free PMC article.
-
The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials.CMAJ. 2008 Feb 26;178(5):576-84. doi: 10.1503/cmaj.070675. CMAJ. 2008. PMID: 18299547 Free PMC article.
-
Selenium, antioxidants, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.Am J Clin Nutr. 2020 Dec 10;112(6):1642-1652. doi: 10.1093/ajcn/nqaa245. Am J Clin Nutr. 2020. PMID: 33053149 Free PMC article.
-
The clinical significance of continuous ECG (ambulatory ECG or Holter) monitoring of the ST-segment to evaluate ischemia: a review.Prog Cardiovasc Dis. 2013 Sep-Oct;56(2):195-202. doi: 10.1016/j.pcad.2013.07.001. Epub 2013 Aug 16. Prog Cardiovasc Dis. 2013. PMID: 24215751 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical